Laboratories

Print

Experimental Chemotherapy

Update : 2020-03-27

Overview

Cancer treatments have dramatically improved during past 2 decades, we are still facing problems to surmount in prevention and therapy of cancers. Recent advances in molecular-targets of cancers have provided the rationale for the molecular-targeted therapy to treat cancer, and often showed market tumor shrinkage. The aim of this research division is to identify possible targets, to clarify the function of molecular targets by analyzing cancer patients derived specimens including pre-treatment and treatment refractory tumors, and ultimately to develop an effective molecular-targeted therapy of cancer. For this purpose, we are investigating the molecular mechanisms of anti-cancer drug resistance, apoptosis resistance, and tumor metastasis. In addition, we are investigating the nature of cancer stem cells.

Projects

  1. Resistance mechanisms to molecular targeted therapy, and therapeutic strategies to overcome the resistance
  2. Targeting tumor cell-platelet interactions for cancer therapy
  3. Targeting cancer stem cells and their regulation
  4. Molecular mechanisms of survival signaling pathways

 

Publications

Publications

*Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata A, Shaw AT, Nishio M, Fujita N, Isoyama T.
The new-generation selective ROS1/NTRK Inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature Commun. 2019; Aug 9;10(1):3604
Gong B., Kiyotani K., Sakata S., Nagano S., Kumehara S., Baba S., Besse B., Yanagitani N., Friboulet L., Nishio M., Takeuchi K., Kawamoto H., Fujita N., *Katayama, R.
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med, 216(4):982-1000. (2019)
Okada, K., Araki, M., Sakashita, T., Ma, B., Kanada, R., Yanagitani, N., Horiike, A., Koike, S., Oh-Hara, T., Watanabe, K., Tamai, K., Maemondo, M., Nishio, M., Ishikawa, T., Okuno, Y., Fujita, N. and *Katayama, R.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine, 41:105-119. (2019)
Ukaji T, Takemoto A, Katayama R, Takeuchi K, and Fujita N.
A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget, 9, 33322-33336 (2018)
Uchibori K, Inase N, Nishio M, Fujita N, Katayama R.
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment. J Thorac Oncol. 13:915-925.(2018)
Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R.
Brigatinib overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Commun., 8: 14768, 2017.
R. Katayama
Therapeutic strategies and mechanisms of drug resistance in Anaplastic Lymphoma Kinase (ALK)-rearranged lung cancer. Pharmacol. Ther., 117, 1-8 (2017)
Takemoto, A., Okitaka, M., Takagi, S., Takami, M., Sato, S., Nishio, M., Okumura, S., Fujita, N.
A critical role of platelet TGF-β release in podoplanin-mediated tumour invasion and metastasis. Sci. Rep., 7: 42186, 2017.
Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Gainor, J.F., Motoi, N., Dobashi, A., Tambo, Y., Kitazono, S., Sato, S., Koike, S., lafrate, A.J., Mino-Kenudson, M., Ishikawa, Y., Shaw, A.T., Engelman, J.A., Takeuchi, K., Nishio, M., Fujita, N.
P-glycoprotein mediates ceritinib resistance in ALK-rearranged non-small-cell lung cancer. EBioMedicine, 3: 54-66, 2016.
Sekiguchi, T., Takemoto, A., Takagi, S, Takatori, K., Sato, S., Takami, M., Fujita, N.
Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 7: 3934-3946, 2016.
Katayama, R., Kobayashi, Y., Friboulet, L., Lockerman, E.L., Koike, S., Shaw, A.T., Engelman, J.A., Fujita, N.
Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer.
Clin. Cancer Res., 21. 166-174, 2015.
Katayama, R., Friboulet, L., Koike, S., Lockerman, E.L., Khan, T.M., Gainor, J.F., Iafrate, A.J., Takeuchi, K., Taiji, M., Okuno, Y., Fujita, N., Engelman, J.A., Shaw, A.T.
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Clin. Cancer Res., 20, 5686-5696 (2014)

Contact

Ryohei Katayama(Chief)
3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan
Tel:81-3-3520-0111 Fax:81-3-3570-0484
E-mail:ryohei.katayama@jfcr.or.jp

 

Return to Top of Page